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ABSTRACT
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response,
while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
poor outcome. Allogeneic hematopoietic cell transplantation (HCT) still represents the only curative approach, but is not so
frequently feasible, because of patient’s fitness, donor availability, and the ability to achieve a remission prior to HCT. The esti-
mated remission rates with conventional cytotoxic agents are around 30%, but they are short-lived. These disappointing results
led to the introduction of new immunologic-based treatments—blinatumomab and inotuzumab. They produced a substantial
improvement in terms of response rates, with the ability, inmost cases, to induce aminimal residual disease (MRD)-negative sta-
tus. Similarly, T cells engineered to express a CD19-specific chimeric antigen receptor (CAR-T) have yielded sensational results
among patients with relapsed/refractory B-ALL, with unexpectedly high MRD-negative complete remissions rates. However,
the first studies looking at long-term outcomes after CAR-T infusions told us that a significant fraction of such responses are not
durable, and may benefit from a consolidation approach such as an allogeneic HCT.
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
1. INTRODUCTION
Over the last few years, several studies confirmed the usefulness of
a pediatric-type therapy applied to adult patients with B-cell acute
lymphoblastic leukemia (B-ALL). Current therapies for adults with
newly diagnosed B-ALL are associated with complete remission
(CR) rates of 60%–90%. For those with relapsed or refractory (R/R)
B-ALL chemotherapy is able to induce 31%–44% CR in first and
18%–25% in second salvage therapy [1]. For patients who achieve
a second CR after re-induction chemoimmunotherapy, allogeneic
hematopoietic cell transplantation (HCT) is still considered the
standard of care (SC). The most relevant, predictive factor of
better clinical outcome in B-ALL is the absence ofmeasurable resid-
ual disease (MRD) in the marrow after intensive multi-agent cyto-
toxic chemotherapy [2]. Persistent MRD at the time of allogeneic
HCT is also associatedwith relevant relapse rates [3]. New immune-
targeted therapies, including drugs targeting B-cell-associated anti-
gens such as CD20, CD19, and CD22 may potentially circumvent
B-ALL cells’ chemo-refractoriness through novel mechanisms of
action, and potentially eradicate MRD, enabling more patients to
receive allogeneic HCT in aMRD-negative status, for better clinical
outcomes.
*Corresponding author. Email: shostakowitsch@libero.it
Peer review is under the responsibility of IACH
2. CONVENTIONAL CHEMOTHERAPY
2.1. Cytarabine-Based Regimens
A retrospective analysis of 40 adults with R/R ALL receiving the
MEC regimen—a combination of cytarabine 1 g/m2/day, etopo-
side 100 mg/m2/day, and mitoxantrone 8 mg/m2/day for 5 days—
showed a CR rate of 30%, with median event-free survival (EFS) of
11.2 months and 30-day mortality of 7.5% [4]. Another retrospec-
tive study on 46 adults with R/R ALL treated with cytarabine and
mitoxantronewith orwithout etoposide showed an overall response
rate (ORR) of 48%, with nearly half of the responders receiving an
allogeneic HCT. The median overall survival (OS) was 6.2 months
and the nonrelapse mortality (NRM) was 15% [5]. The unusual
association of cytarabine 3 g/m2/daily for 5 days with amsacrine at
200 mg/m2/daily for 3 days was reported to be highly active among
36 R/R ALL in a previous report, with an overall remission rate of
75% [6].
2.2. Clofarabine-Based Regimens
Clofarabine (CLO), a second-generation nucleoside purine ana-
logue, is currently approved by the Food and Drug Administration
(FDA) and European Medicines Agency (EMA) for patients up to
the age of 21 with R/R ALL after at least two prior regimens. How-
ever, experience among adult patients is scarce. The first reports on
the use of CLO as a single agent at 40 mg/m2 showed ORR of 17%
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[7,8]. Later on, the Spanish group PETHEMA and the Southwest
OncologyGroup (SWOG) reported on their experiences usingCLO
in R/R ALL adult patients. In the former study, of 31 heavily treated
patients, one-third achieved a CR, although the treatment-related
deaths were high at 23% [9]. In the SWOG S0530 trial, Advani
et al. described the outcomes of 37 patients, 59% harbouring poor
risk cytogenetics, treated with the combination of CLO and cytara-
bine at 1 g/m2 daily, for 5 days. CR rates were 17%, with an OS
of only 3 months [10]. The subsequent S0910 trial, based on the
previously tested association of CLO and cytarabine, evaluated the
introduction of the anti-CD22 monoclonal antibody epratuzumab
in 31 adults with R/R ALL. The ORR was 52%, with an OS of
5 months [11]. A retrospective analysis of the Group for Research
on Adult Acute Lymphoblastic Leukemia reported on results in 55
R/R ALL patients treated with the combination of CLO and con-
ventional drugs, in an intensive schedule treatment programme
with two different regimens (ENDEVOL, n = 18 and VANDEVOL,
n = 37). CR was achieved by 50% of the patients and up to 35%
could proceed to allogeneic HCT [12]. The association of CLOwith
cyclophosphamide +/- etoposide has also been evaluated in a num-
ber of trials, with variable efficacy [13], some of them still ongoing
(NCT01462253, NCT03136146).
2.3. Liposomal Vincristine
Efficacy has been tested as a single-agent drug in 65 R/R ALL
Ph-negative adult patients in a multicenter, single arm phase II
trial. The ORR was 20%, with a median response duration of
5.8 months. Grade 3 neuropathy was seen in 23% of cases. A total of
19% of responders went on to receive an allogeneic HCT [14]. The
FDA approval for adults with Ph-negative ALL in second or greater
relapse was based on these results (Table 1).
3. IMMUNOLOGIC APPROACH
3.1. Inotuzumab
A humanized anti-CD22 monoclonal antibody conjugated to the
cytotoxic antibiotic agent calicheamicin was demonstrated as
highly efficacious in B-ALL patients with R/R disease. CD22 is a
135-kDa B-cell-specific adhesion molecule which is preferentially
expressed onmature B lymphocytes. The normal function of CD22
is to regulate signal transduction from the surface immunoglob-
ulin receptors on B-cells. CD22 is expressed on most blasts from
60% to 90% of B-cell malignancies [15]. Preclinical and phase 1
studies evaluated the safety, antitumor activity, pharmacokinetics,
and pharmacodynamics of Inotuzumab (InO) for CD22-positive
R/R ALL [16]. Findings from INO-VATE, a phase 3, open-label,
randomized study, showed that patients who received InO had sig-
nificantly higher CR rates (81% versus 29%; P < .001), a lower
disease burden during remission (78% versus 28% had bone mar-
row blasts below the threshold for MRD), and more durable
remission (median duration of remission, 4.6 versus 3.1 months),
compared to patients who received the investigator’s choice of
standard chemotherapy (Table 2) [17]. Preliminary data have shown
that InO may also be used in combination with chemotherapy in
order to improve the rate of remission in relapsed B-cell ALL. In
a recent paper by Jabbour et al., the combination of InO with low-
intensity chemotherapy (mini-hyper-CVD) for Ph-negative ALL
patients in first relapse showed a 78% ORR, with a CR rate of 59%
(82% MRD-negativity among responders). Of interest, 44% of the
patients underwent allogeneic HCT, with a 15% incidence of veno-
occlusive disease (VOD) of any grade [18] In fact, VOD is a major
adverse event (AE) associated with InO therapy, being observed in
11% of the cases examined [19]. Prophylactic pharmacologic agents
are recommended for VOD prevention, and in patients for whom
HCT is planned, the number of InO cycles should be limited to
two, leaving at least four to six weeks interval between drug infu-
sion and the start of the conditioning regimen for allogeneic HCT.
Other important or serious InO-related AEs include both haema-
tological and nonhaematological toxicities: febrile neutropenia,
thrombocytopenia, infusion-related reactions, tumor lysis syn-
drome, and prolonged QT syndrome [20]. A report from an
expert panel of haematologists and transplant physicians has
summarized the recommendations for evaluation and manage-
ment of the important AEs associated with InO, with a focus
on diagnosis, prevention, monitoring, and management of VOD
[21]. The possible interventions included prophylaxis medications,
patient monitoring and assessment, and InO dose adjustment or
discontinuation. The application of these recommendations in our
daily clinical practice, as well as the consolidated use of InO in ALL
have significantly reduced the frequency of severe and mild AEs
related to InOadministration (Table 3). A recent study has also eval-
uated the quality of life (QoL) in ALL patients receiving InO. All
subjects completed the European Organization for Research and
Table 1 Conventional chemotherapy trials.
Drug Study No. of Patients ORR (%) Median OS (Months)
Cytarabine (5 g/m2) + Mitoxantrone (40 mg/m2)
+ Etoposide (500 mg/m2)
Liedtke et al. [4] 40 30 6.5
Cytarabine (5 g/m2) + Mitoxantrone (40 mg/m2)
+/- Etoposide (500 mg/m2)
Ahn et al. [5] 46 48 6.2
Cytarabine (15 g/m2) + Amsacrine (600 mg/m2) Arlin et al. [6] 40 72 n.a.
Clofarabine-based regimens (n = 5 CLO-single
agent)
Barba et al. [9] 31 31 5.0
Clofarabine (200 mg/m2) + Cytarabine (5 g/m2) Advani et al. [10] 37 (phase II trial) 17 3.0
Clofarabine (200 mg/m2) + Cytarabine (5 g/m2)
+ Epratuzumab (360 mg/m2 × 4 doses)
Advani et al. [11] 31 (phase II trial) 52 5.0
Clofarabine (120 mg/m2) + Cyclophosphamide
(1.2 g/m2)
Faderl et al. [13] 50 (phase I trial) 14 3.0
Liposomal Vincristine (2.25 mg/m2 weekly) O’Brien et al. [14] 65 (phase II trial) 35 4.6
ORR: Overall response rate; OS: Overall survival.
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Table 2 Monoclonal antibody trials.
Drug Study No. of Patients ORR (%) MRD Rate (%) Median OS (Months) HCT Rate (%)
Inotuzumab Kantarjian et al. [17] 218 81 78 7.7 41
Inotuzumab Jabbour et al. [18] 59 78 82 11.0 44
Blinatumomab Kantarjian et al. [33] 405 44 76 7.7 24
Blinatumomab Topp et al. [32] 189 43 82 6.1 40
Blinatumomab Gokbuget et al. [40] 116 n.a. 78 36.5 67
ORR: Overall response rate; MRD: Measurable residual disease; OS: Overall survival; HCT: Hematopoietic cell transplantation.
Table 3 General recommendation for prevention or monitoring of
veno-occlusive disease (VOD) in patients receiving Inotuzumab.
VOD Prevention VODMonitoring
Avoid HCT conditioning
regimens containing dual
alkylating agents, thiotepa, or
both
In patients who have had severe or
ongoing VOD, follow
recommendations in country-
specific prescribing information to
determine appropriate use of InO.
Use prophylactic agents
(ursodeoxycholic acid,
defibrotide—experimental)
In patients proceeding to HCT,
closely monitor LFTs during the
first month post-HCT, then less
frequently thereafter based on
standard practice.
Among patients proceeding to
HCT, limit treatment with InO
to maximum two cycles
Daily weight monitoring for fluid
retention evaluation.
Monitor ALT, AST, total bilirubin,
and alkaline phosphatase levels
before and after each InO infusion
and adjust InO dose accordingly.
ALT:Alanine aminotransferase; AST: Aspartate aminotransferase; HCT:Hematopoietic cell
transplantation; LFT: Liver function test; ULN: Upper limit of normal; InO: Inotuzumab
Treatment of Cancer (EORTC)-QoL Questionnaire and the Euro-
QoL 5 Dimensions Questionnaires, at baseline, on day 1 of each
cycle, and at the end of treatment [22]. The current patient-reported
outcome data support the favourable benefit/risk ratio of InO for
the treatment of R/R ALL, with superior clinical efficacy and better
QoL, as compared with SC.
The pattern of CD22 expression onALL blasts can be of importance
in predicting disease response to InO [23]. In the INO-VATE study,
a cutoff value of 90% positivity on ALL cells was not a significant
determinant of InO response (79.2% versus 82.4%) [17]. However,
both the percentage of positivity and the intensity of expression
for CD22 antigen appear to be heterogeneous, ranging from 1% to
99% as a percentage of positive blasts, and from dim to very strong
expression, as determined by the antigen expression level in single
blast cells [24,25]. The implication of these findings may be of clin-
ical value and could guide MRD detection [26], since it is known
that immune-targeted therapies such as InO induce a rapid recep-
tor down-modulation, forcing the flow cytometry operator to use
alternative strategies to detect MRD [27]. In this regard, the signif-
icance of MRD among R/R ALL exposed to monoclonal antibody
therapies such InO as salvage treatments, has been recently ques-
tioned [28].
Mechanisms of cell resistance may play a role in B-ALL exposed
to InO. The effective destruction of target cells by InO requires the
completion of a number of steps, including the successful deliv-
ery of antibody–drug conjugate to the tumor microenvironment,
binding of the CD22 molecule, receptor internalization, hydroly-
sis of the chemical linker, activation of calicheamicin by cytoplas-
mic thiols, and the action of calicheamicin on DNA before cellular
efflux [29]. It is unknown which of these factors may explain dif-
ferences in efficacy observed for InO-treated ALL. Although drug
efflux has not been investigated in this setting, previous studies
with gemtuzumab ozogamicin showed that increased expression of
efflux pumps for calicheamicin-reduced gemtuzumab efficacy [30].
Furthermore, patients in first salvage had a higher rate of response
than those in second salvage (87.7% versus 66.7%). On the contrary,
age was not a determining factor in the response rate to InO, since
patients below or above 55 years old had similarly high response
rates to InO (80.3% versus 81.4%). Finally, disease extensionmay be
considered a predicting factor, as patients with a high disease bur-
den (50% bone marrow blasts) showed a high response rate to InO
treatment compared to SC (86.7% versus 77.9%) [31].
3.2. Blinatumomab
A bi-specific T cell engager monoclonal antibody that links CD19-
positive cells to CD3-positive T-lymphocytes, was shown to be one
of the most interesting new drugs used for R/R ALL to date. The
multicenter, single-arm phase-2 study conducted by Topp et al.
among 189 adult patients with primary R/R Ph-negative ALL dis-
closed a surprisingly high CR rate of 43%. The majority of patients
who achieved CR did so within the first cycle (78%), and 82% of
these patients had an MRD response. Of those patients achieving
a response, approximately 40% went on to receive an allogeneic
HCT [32]. In a subsequent international phase-3 clinical trial con-
ducted on 405 pretreated adults affected by R/R Ph-negative ALL,
blinatumomab (BLI) demonstrated superior rates of OS (7.7 ver-
sus 4 months), EFS (31 versus 12% at 6 months), and CR (34 ver-
sus 16%) as compared to cytarabine-based chemotherapy (Table 2).
Lower marrow blast counts were associated with increased CR
(65% versus 34.4% for marrow blasts <50% or ≥50%, respec-
tively), suggesting that the BLI effectiveness requires low-tumor
burden [33]. The favourable results obtainedwith the incorporation
of BLI in sequential combination with Hyper-cyclophosphamide-
vincristine-doxorubicin-dexamethasone (CVAD) among newly
diagnosed ALL adult patients could also serve as an effective asso-
ciation in the R/R ALL setting [34].
The most frequent AEs were nonspecific symptoms, like fever,
headache, fatigue, and infections. Cytokine release syndrome (CRS)
and neurotoxicity appear to be a BLI-specific reaction, commonly
observed also with anti-CD19 CAR-T cells mediated by activated T
cells and pro-inflammatory interleukins [35]. The clinical hallmark
of CRS is represented by high-grade fever into a systemic inflam-
matory response, leading, in the most severe situations, to capillary
Pdf_Folio:87
88 E. Maffini et al. / Clinical Hematology International 1(2) 85–93
leak syndrome associated with hypoxia and hypotension, requiring
intensive care support. High leukemia burden seems to correlate
with higher risk of developing severe CRS [36]. Corticosteroids are
the mainstay treatment of grade 3/4 CRS, while anti-interleukin-
6 may be effective, as already observed with CAR-T-associated
CRS [37]. Neurologic toxicity is dose-limiting, may appear as an
acute or subacute process and may be life-threatening [38]. Its
underlying mechanism is still unknown, although recent evidence
indicates a putative role played by both T and B-lymphocytes, and
macrophages, within a disrupted blood–brain barrier. Endothe-
lial activation and high levels of cytokines in the cerebrospinal
fluid may also be implicated in its pathophysiology. Fascinating
new suggestions propose an unexpected role of interleukin-1 in
anti-CD19 immunotherapy-associated neurologic toxicity [39].
BLI-associated neurotoxicity includes a wide spectrum of clin-
ical pictures, ranging from dizziness, paraesthesia, tremor, to
more serious acute delirium, encephalopathy, convulsions,
dysarthria, and ataxia. Treatment, whenever indicated, is based
on corticosteroids.
The ability of BLI to induce undetectable MRD in the phase II
(BLAST) study of 116 B-ALL adults in hematologic remission with
MRD-positivity led to FDA and EMA-approval. An impressive 78%
of the evaluable patients achievedMRDnegativity after one 28-days
cycle, which was associated with longer OS and EFS than in nonre-
sponders. Any grade CRS and grade 3/4 neurotoxicity occurred in
3% and 13% of patients, respectively. Although 67% of the patients
received an allogeneic HCT, the study was not powered to test
the role of transplant in this setting [40]. The subsequent long-
term follow-up analysis showed a net survival benefit for those
patients achievingMRD-negativeCRafter cycle 1 and for thosewho
received an allogeneic HCT without MRD at the time of transplan-
tation [41].
Recent data on long-term follow-up of 35 R/R ALL treated in a
phase II trial with BLI showed that, of the 19 patients who achieved
a response (84% with MRD-negativity), 16 did relapse at a median
of 3 months, 25% of whom with CD-19 negative relapses. Seven-
teen patients received an allogeneic HCT. The median OS was 10.6
months. Long-term survivors were observed only among thosewho
underwent an allogeneic HCT either as a consolidation approach
after BLI or as part of a salvage treatment after other anti-CD19
therapies, including CAR-T infusions [42].
There are various mechanisms of resistance to BLI in ALL.
Although CD19 modifications, including epitope-loss or alter-
native splicing, or even complete antigen loss variants, have
been observed [43], CD19-negative relapses after BLI exposure
are not so frequent, as CD19 down-regulation by ALL blasts is
quite uncommon [44]. Lineage-switch to acute myeloid leukemia,
although infrequent, has also been reported [45]. Upregula-
tion of programmed death-ligand 1 (PD-L1) offers ALL cells
another viable immunological escape from BLI [46]. Simultaneous
PD-L1-blockade may foster BLI activity, offering a novel potential
therapeutic platform.A recent report fromaphase I dose-escalation
trial confirmed the safety and efficacy of BLI with nivolumab, with
a reported MRD-negative CR rate of 80% among eight treated
patients [47]. Dose escalation will also include anti-CTLA4 ipili-
mumab, in order to augment BLI cytotoxicity (NCT02879695), as
observed in preclinical models [48]. The ongoing NCT03160079
clinical trial is also testing the efficacy of a BLI and pembrolizumab
combination among R/R ALL patients. Irrespective of the exact
mechanism of resistance, ALL patients failing BLI have a poor out-
come, with a median OS of 5.2 months estimated [49].
3.3. CAR-T Cell Therapy
CD19-directedCAR-T have generated unforeseen clinical
responses among notoriously hard to treat R/R ALL patient popu-
lation. However, the majority of the remissions achieved to date are
not durable, and do need consolidation with an allogeneic HCT.
The most frequently observed anti-CD19 CAR-T-associated tox-
icities are, as already mentioned for BLI, CRS and neurotoxicity,
either of which can be fatal. We have summarized below some of
the most influential clinical experiences with CAR-T in R/R ALL
patients.
ELIANA was the first global CAR-T cell therapy registration trial
ever undertaken. It led to FDA-approval, in August 2017, of 4-
1BB/CD3𝜁 Tisagenlecleucel for pediatric and young adults below
25 years of age with R/R ALL [50]. It enrolled a total of 92 patients
(median age 11, range: 3–23) with a median of three prior lines of
therapy and 61% of post-allogeneic HCT relapses. At six months
EFS andOSwere 67% and 78%, respectively (Table 4). In the update
analysis of 75 treated patients (53 of them evaluable for response),
with a median follow-up of 13.1 months, the ORR was 81%, with
60% of CRs. CTL019 was detected in the blood up to 20 months
after the infusion. The 12-month EFS and OS were 50% and 76%,
respectively. A total of 46% of patients developed CRS grade 3
or 4, and 47% were admitted to the intensive care unit (ICU) for
aggressivemanagement.Neurologic eventswere observed in 40%of
patients within eight weeks from infusion with 13% grade 3 but no
grade 4 reported. Only eight patients went on to receive allogeneic
HCT, and all of them were alive at last follow-up [51]. Results from
the long-term follow-up of the Memorial Sloan Kettering Cancer
Centre home-manufactured CAR-T cell phase-I trial among 53 R/R
B-ALL heavily pretreated adult patients were recently published
[52]. At a median follow-up of 29 (range, 1–65) months, median
EFS and OS were 6.1 and 12.9 months, respectively, with a CR
rate of 83%. Patients in hematologic CR prior to CAR-T infusion
had enhanced remission duration and survival, with median EFS
and OS of 10.6 and 20.1 months, respectively. Sixteen of the thirty-
two patients who had a MRD-negative CR suffered disease relapse,
including 25% of CD19-negative relapses. A total of 17 patients
Table 4 Chimeric antigen receptor T cells (CAR-T) trials.
Drug Study No. of Patients ORR (%) Median OS (Months)
Anti-CD19 CAR T cell Maude et al. [51] 40 81 Not reached
19–28z - Anti-CD19 CAR T cell Park et al. [52] 75 (53 evaluable) 83 12.9
Anti-CD19 CAR T cell Turtle et al. [53] 29 93 Not available
41BB - Anti-CD22 CAR T cell Fry et al. [59] 21 57 Not available
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did receive an allogeneic HCT as a consolidation treatment after
CAR-T cell-therapy. Among patients who achieved MRD-negative
CR after CAR-T cell infusion, the authors did not observe a sur-
vival advantage of those who received a subsequent allogeneic HCT
(n = 16) as compared to those who were not transplanted (n = 16).
Severe CRS occurred in fourteen patients with one death reported.
Patients without morphologic remission before treatment or with
extramedullary disease had a greater incidence of CRS, neurologic
toxicity, and shorter long-term survival. In contrast with other stud-
ies, there was no correlation between the persistence of in vivo
CAR-T cells and survival rates, while higher ratios of peak CAR-
T cell concentrations to tumor burden at baseline were signifi-
cantly correlated to survival. Turtle et al. reported on the Fred
Hutchinson Cancer Research Centre’s experience with their phase
I/II trial of anti-CD19 CAR-T cell construct with a 4-1BB costim-
ulatory domain and a fixed CD4/CD8 cell ratio in adults with R/R
ALL [53]. The enrolled patients had previously received a median
of three lines of intensive therapy regimens, and 37% had relapsed
after a prior allogeneic HCT. The authors reported MRD-negative
CR in 27 of 29 patients treated with CAR-T cells. Severe neuro-
toxicity occurred in 50% and CRS in 83% of the patients (28% of
them requiring ICU care). Interestingly, the addition of fludara-
bine in the preparative regimen prolonged CAR-T cell persistence
and EFS rates. Their recently published long-term (median 30.9
months) follow-up analysis, not surprisingly, showed that patients
who achieved MRD-negative CR before CAR-T infusion showed
superior EFS (median 7.6 versus 0.8 months) and OS (median 20
versus 5months) rates as compared to thosewithMRD-positive sta-
tus. High levels of platelets and low lactate dehydrogenase serum
concentration before cell infusion, and the incorporation of flu-
darabine in the lymphodepletive conditioning regimen, predicted
lower survival rates among MRD-negative CR patients. Of note,
a total of 22 of the 45 patients who reached MRD-negative CR
suffered disease relapse, at a median of 3.5 months after CAR-T
infusion. CD19-associated relapses were associated with CAR-T
cell disappearance, while CD19-negative relapses were noted with
ongoingCAR-T cell activity in the patient’s blood.Of the 45 patients
who achieved a CR after cell therapy, eighteen received an allo-
geneic HCT and displayed longer, as EFS compared to those who
did not undergo a transplant (hazard ratio 0.31 95% CI 0.13–0.79)
[54]. As already discussed, antigen loss is a cause of resistance to
CD19-targeted immunotherapy. Acquired mutations and/or alter-
native splicing are possible mechanisms of immunological-escape
from antiCD19 CAR-T [55]. CD19 isoforms could preexist at diag-
nosis and could, under therapy-induced selective pressure, evolve
as a dominant clone [56]. Immunologic escape through the acqui-
sition of a myeloid phenotype has been described for anti-CD19
CAR-T therapy [57]. Of relevant interest, preclinical models sug-
gest that a state of T cell exhaustion may influence the response to
CAR-T therapy. A complex network of cytokine milieu, produced
by ALL blasts, promotes persistent up-regulation of inhibitory
receptors, including PD1, Tim3, and LAG3 on T cell surface. Such
T cell dysfunctional state does persist following the introduction
of CAR-T constructs, impairing their activity and functionality
[58]. CD22 is usually retained by ALL leukemic blasts, even after
CD19 loss, representing a potential therapeutic target for cell-based
therapies. Encouraging results came from a phase I trial, conducted
with a novel lentiviral vector-transduced anti-CD22 CAR-T, among
21 R/R ALL patients, including 17 who relapsed after a previous
exposure to anti-CD19 CAR-T cell. CR was observed in 57% of the
patients with a reported median response duration of 6 months.
Reduced and variable CD22 antigen site density on B-ALL cells rep-
resented the putative primary resistance factor in almost all relapsed
patients [59]. In order to minimize ALL blast cells’ immunologic
escape after traditional mono-directed CAR-T cell therapy, the sci-
entific community is evaluating the feasibility and efficacy of bi-
target antigenCAR-T cell formulations. Investigators fromStanford
University presented their data from a Phase I trial with a bi-specific
CD19/22 CAR-T construct. A total of seven adult patients affected
by B-cell malignancies (two ALL) were treated, and a subsequent
expansion study with estimated 60 patients will follow [60]. The
same Institution performed another phase I escalation study among
pediatric patients with R/R ALL with promising results [61]. Gard-
ner et al. reported on Seattle’s Children experiencewith a dual trans-
ducedCD19/22CAR-T cell product among seven pediatric patients
with R/RALL. Five of the seven subjects achieved CR, four of which
were MRD-negative. The separate dual lentiviral transduction pro-
cess generated a mixture of three different in vivo CAR-T popula-
tions (anti-CD19; anti-CD22; anti-CD19 +CD22). Surprisingly, the
authors observed a selective in vivo expansion of the CD19 CAR
T cell population over the remaining counterparts [62]. Investiga-
tors from China developed a bi-specific product from autologous
sequentially-transduced CD19 and CD22 CAR-T cell constructs.
Data from the phase I trial conducted among 19 R/R ALL adult
patients showed a 95% ORR at day 30, with 94.4% MRD negativ-
ity. Of the fourteen patients who received a subsequent allogeneic
HCT after a median of 61 days, none relapsed, while 75% of non-
transplanted patients suffered from both CD19- and CD22-positive
disease relapse [63].
Genome-editing technologies such as transcription activator-like
effector nuclease (TALEN) and CRISPR-Caspase 9 represent ideal
platforms to generate third-party, off-the-shelf CAR-T cells [64].
The international, multi-centre phase I clinical trials of the off-the-
shelf CAR-T product UCART19 has recently started recruitment
for adult (from 16 to < 70 years) R/R ALL (NCT02746952, CALM
study).
4. ALLOGENEIC HCT
Allogeneic HCT is the standard frontline therapy for patients with
Ph-negative ALL at high risk of relapse. Historical donor versus
no-donor studies have clearly shown improved outcome follow-
ing allogeneic HCT, as compared to conventional chemotherapy
in this setting [65,66]. Such data, together with the evidence of a
strong graft-versus-leukemia effect in ALL [67], prompted the use
of allogeneic HCT in first CR in order to prevent leukemia relapse.
Nevertheless, the role of allogeneic HCT in ALL has been recently
redefined bymajor changes in clinical practice, including the intro-
duction of pediatric-like regimens [68], the availability of novel
salvage therapies, and the widespread use of MRD assessment.
Unfortunately, allogeneic HCT still carries significant NRM risks,
which should be counterweighted by the expected reduced risk of
relapse, considering disease biology (cytogenetics, phenotype, ele-
vated initial white blood cell count) and kinetics of response to
induction chemotherapy. Recently, the Adult Acute Lymphoblas-
tic Leukemia (EWALL) and the Acute Leukemia Working Party
of the European Society for Blood and Marrow Transplantation
(EBMT) groups joined together with the aim of producing a posi-
tion statement on transplantation in ALL [69]. There is broadPdf_Folio:89
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consensus that allogeneic HCT should be offered to R/R ALL
patients, after they enter a second remission. Any available thera-
peutic options employed as salvage treatment should be attempted
to bring patients into remission at the time of transplant, as the
outcome of patients with active disease or even positive MRD at
the time of transplant is poor [70–72]. The indications for allo-
geneic HCT in first CR are significantly more heterogeneous: cur-
rently, most authors recommend offering transplant to “younger
adults” (defined as <50–65 years, the cut-off age limits being highly
variable among experts) in first CR with MRD positivity after
induction/early consolidation, or to patients with adverse disease
characteristics, irrespectively of MRD status. Among these cri-
teria, MRD is the most consistent, although with different cut-
offs and evaluation time points. Overall, MRD positivity after
early consolidation is considered a strong predictor of relapse and,
therefore, such patients should be offered allogeneic HCT. Older
adults have a significantly poorer outcome following allogeneic
HCT with a reported long-term EFS of less than 35% [73]. In
fact, there is no consensus about indications for transplant in this
setting, and most authors consider transplant an “option” which
should be carefully evaluated balancing comorbidity score, kind of
donor, and disease characteristics. Matched sibling donor (MSD)
is the preferred donor source for allogeneic transplant in ALL, but
10/10-matched unrelated donor (MUD) is considered an accept-
able alternative [74]. If no MSD or 10/10 MUD are available, there
is no agreement among experts on the preferred donor source.
There is evidence that increase in HLA disparities leads to higher
NRM [75], but no prospective study has ever compared differ-
ent donor sources in ALL. In the last decade, T-replete haploiden-
tical transplantation has been increasingly performed worldwide,
following the development of the posttransplant cyclophosphamide
platform, with promising results in different hematological malig-
nancies, including ALL [76]. Nevertheless, recent evidence showed
similar outcome for cord blood and matched/mismatched unre-
lated donors [77]. Therefore, the choice of the donor should be
carefully weighted considering availability, timing, and costs. The
use of autologous HCT in ALL has progressively decreased world-
wide [78]; this strategy could represent an alternative approach
for low risk, MRD-negative patients [79]. Currently, most trans-
plants are performed using peripheral blood stem cells (PBSCs)
worldwide, and ALL does not represent an exception. The inclu-
sion of antithymocyte globulin in the preparatory regimen is
associated with reduced incidence of chronic graft versus host dis-
ease without affecting EFS or OS, as evidenced by a recent EBMT
study on patients with Ph-negative ALL undergoing transplant
with PBSC from either MSD/MUD-HCT in first remission [80].
Historically, total body irradiation (TBI) has been the standard con-
ditioning regimen for allogeneic HCT in ALL for many years [81].
TBI is usually combined with either cyclophosphamide or etopo-
side [82,83]. A great body of retrospective studies comparing TBI-
versus chemotherapy-based protocols reported reduced relapse risk
after TBI-including regimens. Nevertheless, it should be high-
lighted that TBI is associated with severe late effects, which include
endocrine dysfunction, cardiovascular and pulmonary sequelae,
and secondary tumors. Recent evidence from a retrospective anal-
ysis highlights the importance of delivering TBI during the con-
ditioning regimen also in the R/R ALL cohort [84]. When a
radiation-free regimen is selected, thiotepa represents an alkyla-
tor commonly included in the preparatory protocol, and recent
retrospective data showed similar survival after thiotepa-based
regimens as compared to TBI [85]. Nevertheless, there is no defini-
tive evidence demonstrating the superiority of one approach over
the other.
5. PRACTICAL MANAGEMENT
CONSIDERATIONS
As already discussed above, the goal of reinduction therapy after
relapse is to obtain a second CR to be consolidated as soon as pos-
sible by an allogeneic HCT. For patients suffering from disease
relapse after two/three years from initial antileukemia treatments,
traditional cytotoxic chemotherapy could represent a viable choice,
after careful assessment of the patient’s fitness and evaluation of
toxic effects associated with previous regimens. In this scenario, the
utilization of new drugs not previously used, such as CLO, may be
potentially effective.
The vast majority of patients with early relapse need an urgent
remission induction in order to be consolidated rapidly by allo-
geneic HCT. CAR-T cell therapy could be a feasible option for
young patients aged ≤ 25 years among carefully selected institutions
with skilled staff and proper resources. Recent insights are confirm-
ing that CAR-T responses may not be durable. The correct identi-
fication of patients at risk of disease relapse after CAR T cell will be
crucial, in order to address them to consolidation strategies such as
allogeneic HCT.
The choice between BLI and InO should be the result of a
fine assessment between drug availability and associated costs,
institution experience, expected patient tolerability estimated
drug-induced toxicities, and disease biologic features (ALL blast
antigenic expression profile).
6. CONCLUSIONS
After years of struggle, novel drugs are effectively changing the
current scenario for R/R ALL patients, bringing the fraction of
responding patients to unexpected high levels, enabling them to
receive an allogeneic HCT as a consolidation treatment. More evi-
dence is needed to better integrate allogeneic HCT with the novel
immunotherapies currently available, in order to improve anti-
leukemic control before and after transplantation.
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